Sangamo Therapeutics Inc (SGMO) reports significant progress in clinical trials and funding, despite facing regulatory uncertainties and cash management hurdles.
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across ...
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across al ...
Sangamo Therapeutics, a company at the forefront of gene therapy and genomic medicine development, has made significant ...
Research presented by Dr Anna Keegan of University College London at the ELRIG meeting in Hinxton described how improved ...
Research presented by Dr Jimena Perez Sanchez at ELRIG in Cambridge has set out how chemogenetics and related gene therapy strategies may reduce chronic pain by dampening hyperactive peripheral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results